Circulation

NOVEMBER 11, 2024

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. in HFD/L-NAME vs E/A=1.4 ± 0.02 vs. Ctrl), indicative of pulmonary congestion.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Hypertension Blood Pressure Obesity 40

Circulation: Heart Failure

SEPTEMBER 12, 2023

BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. mL/kg per min lower peak VO2(β, −2.35±0.19;P<0.001).

Biomarkers 40

Biomarkers Obesity Exercise Preserved Ejection Fraction 40

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

European Journal of Heart Failure

NOVEMBER 19, 2024

Muscle quality and cardiac function in heart failure with preserved ejection fraction (HFpEF) during exercise. Blood pressure was measured manually and mean arterial pressure (MAP) was calculated. Methods and results A total of 22 HFpEF patients and 23 healthy matched controls (CTL) were recruited.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiac Function Exercise Heart Failure 40

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

DAIC

JUNE 26, 2024

The analysis sought to determine whether phenotypic features and treatment effects of semaglutide vary by sex in obesity-related heart failure ( HF ) with preserved ejection fraction (HFpEF). It also lowered their systolic blood pressure and waist circumference. vs -7.2%.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Journal of the American Heart Association

JANUARY 23, 2025

Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2. We found similar associations for HF hospitalization.

Heart Failure 45

Heart Failure Preserved Ejection Fraction Obesity Outcomes 45

Circulation

NOVEMBER 11, 2024

We excluded articles related to acute decompensated HF and HF with preserved ejection fraction. to -0.16, p=0.00) (Figure 1B), were associated with a reduction in systolic blood pressure (MD = -0.32, 95% CI: -0.51 The primary outcome was the change in NYHA functional class (FC). to 0.36, p=0.06) (Figure 1D).

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Disease Preserved Ejection Fraction 40

DAIC

APRIL 9, 2024

There were also no adverse events related to low ejection fraction (a measure of how well the heart pumps blood) and no adverse effects on blood pressure or heart rate. Maron said that a larger phase 3 trial would help shed light on the magnitude of the drug’s potential benefits.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Chest Pain Preserved Ejection Fraction 52

Cardiometabolic Health Congress

JULY 25, 2023

4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), but also in those with coronary heart disease. [5, Carbone, Salvatore, et al. Future Cardiology 13.5

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Key Takeaways: Greater Weight Loss, Greater Benefit : Achieving 2-5% weight loss yields metabolic improvements, while over 15% weight loss significantly reduces obesity-related complications like hypertension, NAFLD, and heart failure with preserved ejection fraction (HFpEF). SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103